The Frequency and Importance of Common [alpha]-globin Gene Deletions Among [beta]-Thalassemia Carriers in an Iranian Population.
The severity of [beta]-thalassemia ([beta]-thal) symptoms is associated with alpha and non [alpha]-globin chain ratio imbalance (1). It is expected that [alpha]-globin gene triplication/quadruplication in a locus can aggravate the clinical phenotype of a defective [beta]-globin gene, although that may be variable in different individuals in severity. On the other hand, deletion of [alpha]-globin genes in combination with beta-thai may ameliorate the clinical condition (2-5).
The national thalassemia screening program for prevention of [beta]-thal major in Iran was initiated based on pre-marital screening since 1997 because of the high prevalence of [beta]-thalassemia. Fetuses affected with thalassemia major can be aborted before 18 weeks of gestational age according to 1998 law permission (6).
The presence of different hemoglobin abnormalities in multiethnic community in Iran makes challenges in the screening program and genetic counseling (7-10). In this regard, the combination of [alpha]-globin numerical variants may change the blood parameters and clinical severity of [beta]-thalassemia (11-13).
A single a-gene deletion co-inheritance effects on [beta][degrees]-thal are very slight, while a milder disease have been seen in [[beta].sup.+] thai individuals with two [alpha]-gene deletions (2,14). Also, moderately severe anemia features are seen in Hb H disease (with only one functional [alpha]-gene) and homozygous [beta]-thal patients (3,5). Although abnormal hematological parameters are not associated with [alpha]-globin gene triplication, there are some reports that indicate co-inheritance of [alpha]-globin gene triplication and heterozygous [beta]-thal alleles might be responsible for [beta]-thal intermedia phenotypes ranging from mild to blood transfusion dependent (2,15-17).
[beta]-thal alleles average frequency is about 4-5% in Iran which could increase to 10% in northern and southern regions of the country while [alpha]-thal carriers frequency in some southern regions is about 30% (18,19). In addition, the carrier frequency of the [alpha][alpha][alpha]anti3.7 triplication or quadruplication has been reported to be 2.14% in individuals with normal hematological indices and 1.7% in individuals with mild microcytosis (14).
In this study, the co-inheritance of [beta]-thal alleles with common [alpha]-globin gene deletions was evaluated in asymptomatic carriers of [beta]-thal in an Iranian population. Then, [alpha]-globin gene deletion cases were examined for [alpha]-globin triplication. Finally, the hematological indices and genetic consequences of this combination were considered.
Materials and Methods
In this study, 227 unrelated [beta]-thal carriers were referred from Primary Health Care (PHC) centers (from 2010-2012) to genetic prenatal diagnosis laboratories. All cases had low hematological indices (MCV <80 fL, MCH <27 pg and Hb A2 >3.4%).
Written informed consent was obtained from all participants in the study. Then, 5 ml peripheral blood was collected in tubes containing EDTA. DNA extracts were obtained from peripheral blood leukocytes by salting out method (20). For common [beta]-globin gene mutation analysis, amplification refractory mutation system, polymerase chain reaction (ARMS-PCR) and for rare [beta]-thal alleles, DNA sequencing was used. Also, for common [alpha]-globin gene cluster deletions (-[alpha]3.7, -[alpha]4.2,--MED and -[alpha]20.5), multiplex Gap-PCR based on Liu et al.'s study was performed (21). Also, to investigate alpha triplication ([alpha][alpha][alpha]anti3.7) in cases with [alpha]-globin gene deletion, multiplex PCR method was set up and used (14).
In this study, the combination of [alpha]-globin gene deletion was investigated in an Iranian population of [beta]-thal carriers referred from Primary Health Care centers. Out of the 227 unrelated asymptomatic [beta]-thal carriers with defined mutation in HBB gene included in the study, 43 individuals (about 19 percent) had one or two [alpha]-globin gene deletions including 37 cases heterozygote for -[alpha] (3,7) with [alpha][alpha]/-[alpha] (3,7) genotype, 5 cases homozygote for -[alpha] (3,7) deletion with -[[alpha].sup.3.7]/-[[alpha].sup.3.7] genotype, and one -MED deletion with [alpha][alpha]/--MED genotype. The co-inheritance of [alpha]-globin gene deletion and triplication was not found in the studied individuals. In figure 1, a representative run of samples tested for [alpha]-globin gene deletions is shown. Also in table 1, important hematological indices were analyzed in beta thal screening in 2 groups.
Mediterranean, African and South Asian areas are more affected by beta-thalassemia. Approximately, Eastern Mediterranean, Europe, Western Pacific, Sub-Saharan Africa, Southeast Asia and America's people are affected by a gene mutation at 2-18, 0-19, 0-13, 0-12, 0-11 and 0-3%, respectively (22,23). Rabbani in his review has pointed that, in beta globin gene there are more than 800 described variants worldwide which can result in beta thalassemia (24,25). In Sardinia (11-34%), Sicily (10%), Greece (5-15%), and Iran (4-10%), HBB mutations are seen frequently (26-30). In Iran, most common beta-thal mutations reported are IVS II-1 and IVS I-5 (31).
Alpha thalassemia is a common single-gene disorder throughout parts of the world where malaria is endemic. Multiple studies have suggested that the presence of both single and double alpha-globin gene deletions has a protective effect against malaria (32,33). The allele frequencies of alpha thalassemia in the Mediterranean basin, portions of West Africa and in parts of Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia are 5-10, 20-30, and 60-80%, respectively. The frequency of heterozygote carrier status among the Chinese population has been reported to range from 5 to 15%. The frequency of alpha thalassemia is lower than 0.01% in Great Britain, Iceland, and Japan (34-36).
Although [beta]-thalassemia results from reduced [beta] hemoglobin synthesis, the amounts of free [alpha]-globin chains can be an important genetic modifier contributing to variation in hematological and clinical phenotypes in patients. The variability in clinical severity of [beta]-thalassemia has been attributed to environmental and genetic factors, including [alpha]-triplication, [alpha]-deletion and Hereditary Persistence of Fetal Hemoglobin (HPFH), HFE variants and some other unknown mutations (1).
The alpha2 gene transcription amounts are two to three times more than alpha 1 gene transcription in alpha gene cluster. So this different expression could result in hemoglobin variant in deletional and nondeletional forms of alpha-thalassemia (37). Alpha-thalassemia based on nondeletion defects happens in low frequencies. Point mutation or oligonucleotide deletions/insertions for alpha globin gene expression could be critical. The most common nondeletional are the T[right arrow]C initiation codon mutation, the -5nt alpha and -IVS1 deletion in Mediterranean and also polyadenylation site mutations in Mediterranean and Middle East populations, Hb Constant Spring and other resemblance elongated variants in Mediterranean, middle East Asia, and Southeast Asia (38). MRNA product of these changes, because of disruption of the untranslated region seems as a reason of product reduction of Hb (39). Also, some mutations of alpha genes could produce hyper unstable globin variants that are unable to form stable tetramers. Harteveld et al have recently reported a complete nondeletional alpha-thalassemia mutation list (40).
In our study, the common [alpha]-giobin gene cluster deletions (-[alpha]3.7, -[alpha]4.2,--MED and -[alpha]20.5) were investigated and -[alpha]20.5 deletion was not seen in our cases, while -[alpha]20.5 deletion was estimated to be about 13.6% in Qazvin province, 1.9 % in Gilan province and 1.5% in Mazandaran province (41-43). Also, in Khuzestan province -[alpha]20.5 deletion has not been detected (44). These results show that samples had Hb Al> 90%. Therefore, because of alpha mutation low occurrences and our limitation for more investigation, the main focus was on alpha common deletions.
As shown in table 1, comparing means of individuals with alpha deletion in beta-thai carriers, alpha deletion can modify mean of indices in beta thalassemia carriers slightly. Means of Hb and MCV alteration were significant and in none of our samples, MCV was more than 80 fl. In MCH category, while our sample size was two times bigger but MCH mean increase in alpha-beta group was not significant. Our sample size for HbA2 and RBC indices was statically small but as seen in table 1, our results had very small differences.
It seems that our investigation results are different from other studies in the same field. It should be noted that in some of the reported studies, comparing is performed between alpha-beta thalassemia with normal cases or in more than two groups but our emphasis was comparison between beta thalassemia carriers with alpha- beta thalassemia carriers in hematology indices so increasing amounts occur in very small scales (8,45).
On the other hand, the frequency of [alpha]-triplication/quadruplication in some populations has been reported. In most cases, [alpha]-triplication occurs at no higher than about 1% of the world population though it has been observed in just over 3% of the Sri Lankan population. Both triplicated and quadruplicated [alpha]-globin-gene arrangements seem to have very little effect in otherwise normal individuals (1). It has been reported that a single additional a-gene had a very limited effect on the betathal minor phenotypes or may produce the mild thalassemia intermedia phenotype with no history of blood transfusion (46).Based on these facts, all of [beta]-thalassemia carriers that had [alpha]-globin genes deletion for alpha globin gene triplication/quadruplication were investigated to ensure that phenotypes of these cases are just related to [beta]-thalassemia and [alpha]-globin genes deletion as genetic factors. The co-inheritance of [alpha]-globin gene deletion and triplication was not found in alpha-beta thalassemia studied individuals. Also, none of the affected persons with [beta]-thalassemia and [alpha]-globin genes deletions showed higher hematological indices than fixed indices in [beta]-thalassemia screening program in Iran.
It seems that in such situations, the nature of HBB mutation, the number of [alpha]-globin genes and other environmental and genetic modifiers should be considered for genotype- phenotype correlation analysis. In our study, our findings indicate that although the [beta]-thalassemia screening program in Iran is not special but it is sensitive enough in isolating people with [beta]-thalassemia as a microcytic hypochromic anemia, even those cases with co-inheritance of common [alpha]-globin genes deletion.
At the present time, still many unclear points exist for prediction of the phenotype and it is confusing for genetic counselors to know exactly what is happening or what should be done to prevent the birth of children with thalassemia (legal and ethical aspects). Further studies are needed to clarify these questions especially in a multiethnic country like Iran.
We thank all of our colleagues in the field of Molecular medicine at the Pasteur Institute of Iran who provided insight and expertise that greatly assisted the research. Also we appreciate the guidances provided by Dr. Masoud M.A. Boojar from Kharazmi University at the beginning of the study.
Conflict of Interest
The authors declare that they have no conflict of interest.
(1.) Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. US: John Wiley & Sons; 2008. 823 p.
(2.) Traeger-Synodinos J, Kanavakis E, Vrettou C, Maragoudaki E, Michael T, Metaxotou-Mavromati A, et al. The triplicated alpha-globin gene locus in beta-thalassaemia heterozygotes: clinical, haematological, biosynthetic and molecular studies. Br J Haematol 1996;95(3):467-471.
(3.) Bragos IM, Noguera NI, Raviola MP, Milani AC. Triplication (/alphaalphaalpha anti3.7) or deletion (-alpha 3.7/) association in Argentinian beta-thalassemic carriers. Ann Hematol 2003;82(11):696-698.
(4.) Kimura EM, Grignoli CR, Pinheiro VR, Costa FF, Sonati MF. Thalassemia intermedia as a result of heterozygosis for beta 0-thalassemia and alpha alpha alpha anti-3,7 genotype in a Brazilian patient. Braz J Med Biol Res 2003; 36(6):699-701.
(5.) Wainscoat JS, Kanavakis E. Wood WG, Letsky EA, Huehns ER, Marsh GW, et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol 1983;53(3):411-416.
(6.) Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ 2004;329(7475):1134-1137.
(7.) Moafi A, Valian S, Nikyar Z, Zeinalian M, Momenzadeh M, Rahgozar S. Prevalence of minor [beta]-thalassemia based on RBC indices among final suspected individuals in premarital screening program referred to genetic laboratories. Int J Hematol Oncol Stem Cell Res 2010;4( 1 ):23-27.
(8.) Irani AD, Cheraghi Z, Bitaraf S, Cheraghi P, Safiri S. Prevalence of alpha and beta-thalassemia mutations among carriers of thalassemia in Shadegan city, southwest of Iran. Zahedan J Res Med Sci 2015;17(8):el032.
(9.) Winichagoon P, Fucharoen S, Chen P, Wasi P. Genetic factors affecting clinical severity in beta-thalassemia syndromes. J Pediatr Hematol Oncol 2000;22(6):573-580.
(10.) Camaschella C, Mazza U, Roetto A, Gottardi E, Parzlale A, Travl M, et al. Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol 1995;48(2):82-87.
(11.) Mettananda S, Gibbons RJ. Higgs DR. [alpha]-globin as a molecular target in the treatment of [beta]-thalassemia. Blood 2015;125(24):3694-3701.
(12.) Fessas P, Stamatoyannopoulos G, Karaklis A, editors. Hereditary persistence of foetal haemoglobin and its combination with alpha and beta-thalassaemia. 8th Congress of European Society of Haematology Vienna: Karger; 1961.
(13.) Thein SL. Genetic modifiers of the beta-haemoglobinopathies. Br J Haematol 2008;141(3):357-366.
(14.) Moosavi SF, Amirian A, Zarbakhsh B, Kordafshari A, Mirzahoseini H, Zeinali S. et al. The carrier frequency of [alpha]-globin gene triplication in an Iranian population with normal or borderline hematological parameters. Hemoglobin 2011:35(4):323-330.
(15.) Camaschella C, Kattamis A, Petroni D, Roetto A, Sivera P, Sbaiz L. et al. Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia. Am J Hematol 1997;55(2):83-88.
(16.) Weatherall D. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001;2(4):245-255.
(17.) Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol 1998; 11(1): 127-146.
(18.) Harteveld CL, Yavarian M, Zorai A, Quakkelaar ED, Van Delft P, Giordano PC. Molecular spectrum of alpha-thalassemia in the Iranian population of Hormozgan: three novel point mutation defects. Am J Hematol 2003; 74(2):99-103.
(19.) Fallah MS, Zadeh-Vakili A, Aleyasin SA, Mahdian R, Karimipour M. Raeisi M, et al. Molecular characterization of thalassemia intermedia, due to co-inheritance of homozygous alpha triplication and IVSI-5 beta-thalassemia. Blood Cells Mol Dis 2009;43(2): 158-160.
(20.) Miller S. Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids Res 1988; 16(3): 1215.
(21.) Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol 2000; 108(2): 295-299.
(22.) Origa R. Beta-Thalassemia [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK1426/.
(23.) Advani P. Beta thalassemia: Background, Etiology, Epidemiology [Internet]. New York: 2016 Nov. Availabe from: http:// http://emedicine.medscape.com/article/20-6490-overview.
(24.) Giardine B, Borg J, Viennas E, Pavlidis C, Moradkhani K, Joly P, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 2014;42(Database issue):D1063-1069.
(25.) Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 2004;32(Database issue):D537-541.
(26.) Guiso L, Frogheri L, Pistidda P, Angioni L, Dore F, Pardini S, et al. Frequency of delta+ 27-thalassaemia in Sardinians. Clin Lab Haematol 1996;18(4):241-244.
(27.) Mahdieh N, Rabbani B. Beta thalassemia in 31,734 cases with HBB gene mutations: pathogenic and structural analysis of the common mutations; Iran as the crossroads of the Middle East. Blood Rev 2016;30(6):493-508.
(28.) Lukens IN. The thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. Wintrobe's Clinical Hematology. 9th ed. Philadelphia: Lippincot William & Wilkins; 1993. p. 1103.
(29.) Haghshenas M. Zamani J. Thalassemia. Shiraz: Shiraz University of Medical Sciences Publishing Center. 1997; 3:50-57.
(30.) Loukopoulos D. Kaltsoya-Tassiopoulou A, Fessas P. Thalassemia control in Greece. Birth Defects Orig Artic Ser 1988:23(5B):405-416.
(31.) Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol 2007;29(4):233-238.
(32.) Bernini L, Steinberg M. Geographic distribution of [alpha]-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin. Cambridge: Cambridge University Press; 2001. p. 878-94.
(33.) Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci 2009;66(7):1154-1162.
(34.) Casas-Castaneda M, Hernandez-Lugo I, Torres O, Barajas H, Cibrian S, Zamudio G, et al. Alpha-thalassemia in a selected population of Mexico. Rev Invest Clin 1998; 50(5):395-398.
(35.) Ko TM. Hwa HL, Liu CW, Li SF, Chu JY, Cheung YP. Prevalence study and molecular characterization of alpha-thalassemia in Filipinos. Ann Hematol 1999;78(8): 355-357.
(36.) Chaibunruang A, Prommetta S, Yamsri S, Fucharoen G, Sae-ung N, Sanchaisuriya K, et al. Molecular and hematological studies in a large cohort of [alpha](0)-thalassemia in northeast Thailand: data from a single referral center. Blood Cells Mol Dis 2013;51(2):89-93.
(37.) Galanello R, Cao A. Gene test review. Alpha-thalassemia. Genet Med 2011;13(2):83-88.
(38.) Higgs DR. The molecular basis of a-thalassemia. Cold Spring Harb Perspect Med 2013;3(l):a011718.
(39.) Hunt D, Higgs DR, Winichagoon P, Clegg JB, Weatherall DJ. Haemoglobin constant spring has an unstable alpha chain messenger RNA. Br J Haematol 1982;51(3): 405-413.
(40.) Harteveld CL. Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis 2010;5:13.
(41.) Sarookhani MR, Asiabanha M. Spectrum of [alpha]-thalassemia mutations in Qazvin province, Iran. Afr J Biotechnol 2011;10(77):17690-17694.
(42.) Tamaddoni A, Hadavi V, Nejad NH, Khosh-Ain A, Siami R. Aghai-Meibodi J, et al. Alpha-thalassemia mutation analyses in Mazandaran province, north Iran. Hemoglobin 2009;33(2):115-123.
(43.) Hadavi V, Jafroodi M, Hafezi-Nejad N, Moghadam SD, Eskandari F, Tarashohi S, et al. Alpha-thalassemia mutations in Gilan province, north Iran. Hemoglobin 2009;33 (3):235-241.
(44.) Zandian K, Nateghi J, Keikhaie B, Pedram M, Hafezi-Nejad N, Hadavi V, et al. Alpha-thalassemia mutations in Khuzestan province, southwest Iran. Hemoglobin 2008; 32(6):546-552.
(45.) Valizadeh F, Deylami A. Prevalence of mutations of alpha globin gene in suspected alpha carrier couples, Babolsar, 2006-2011. Mazandaran Univ Med Sci 2014;23 (109):17-25.
(46.) Giordano PC, Bakker-Verwij M, Harteveld CL. Frequency of alpha-globin gene triplications and their interaction with beta-thalassemia mutations. Hemoglobin 2009:33(2):124-131.
Azam Moosavi (1,2*) and Ali M. Ardekani (3)
(1.) Department of Biochemistry, Faculty of Medicine, Alborz University of Medical Sciences, Alborz, Iran
(2.) Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
(3.) Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
(*) Corresponding author:
Azam Moosavi, MS.c., Department of Biochemistry. Faculty of Medicine, Alborz University of Medical Sciences, Alborz, Iran
Tel: +98 26 34336007
Fax: +98 26 34302090
Received: 27 Aug 2016
Accepted: 28 Dec 2016
Table 1. The mean of hematological indices among beta-thalassemia and alpha-beta-thalassemia carriers Parameters Mean (1)[+ or -]SD Mean(2)[+ or -]SD Hb (g/dl) 12.4[+ or -]1.8 13.1 [+ or -]2.0 RBC(106/ul) 6.10[+ or -]0.7 6.12[+ or -]0.7 MCV(fl) 63.2[+ or -]5.0 65.4[+ or -]6.1 MCH (pg) 20.3[+ or -]2.0 20.9[+ or -]2.2 HbA2 (%) 5.3[+ or -]0.7 5.2[+ or -]0.7 (1.) The mean values with standard deviations for 100 beta-thai carriers without any common alpha deletion are shown in this column for specific parameters (2.) The mean values with standard deviations for 43 individuals with coinheritance of common alpha deletion and beta-thai mutation are shown in this column for specific parameters
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Moosavi, Azam; Ardekani, Ali M.|
|Publication:||Avicenna Journal of Medical Biotechnology (AJMB)|
|Date:||Oct 1, 2017|
|Previous Article:||Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer.|
|Next Article:||Alternative Splicing Generates Different 5' UTRs in OCT4B Variants.|